JPRN-UMIN000006938招募中1 期
Phase I/II clinical trial of novel peptide-based cancer vaccine IMA901 for patients with advanced renal cell carcinoma - Phase I/II clinical trial of peptide-based cancer vaccine IMA901 for patients with renal cell carcinoma
Departments of Urology and Translational Cancer Drug Development, Kyoto Prefectural University of Medicine0 个研究点目标入组 15 人开始时间: 2011年12月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Immunosuppressive therapy within 4 weeks before starting this therapy, e.g. corticosteroid treatment (exceptions are corticosteroid substitution therapy for adrenal insufficiency or inhalative corticosteroids for e.g. asthma) 2. History of other malignant tumors, except non-melanoma-skin cancer or curatively excised cervical carcinoma in situ 3. Presence of brain metastases on MRI or CT scan 4. Patients with a history or evidence of systemic autoimmune disease 5. Any vaccination in the two weeks before starting this therapy 6. Any planned prophylactic vaccination from study entry until the end of the induction period (5 weeks after the first vaccination) 7. Known active hepatitis B or C infection 8. Known HIV infection 9. Any of the following in the 4 weeks before starting this therapy: a) Major surgery b) Anticancer treatments including cytotoxic chemotherapy, radiotherapy, immunotherapy, hormone therapy, molecular-targeted therapy, or monoclonal antibodies c) Unresolved toxicity from prior anticancer treatments including cytotoxic chemotherapy, hormone therapy, molecular-targeted therapy, monoclonal antibodies, radiotherapy, or immunotherapy d) Received study drug within any clinical study (including approved and experimental drugs) 10. Presence of abnormal function in vital organs 11. Active infections requiring oral or intravenous antibiotics 12. Pregnancy or breastfeeding 13. Any condition which in the judgment of the investigator would place the patient inappropriate to be enrolled in this study
研究者
相似试验
已完成
1 期
Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinomaadvanced renal cell carcinomaJPRN-UMIN000004911Department of Urology, Kinki University School of Medicine18
已完成
1 期
Phase I clinical trial of epitope peptides based vaccines both targeting RNF43 and VEGFR2 in patients with advanced colorectal cancer.unresectable colorectal cancerJPRN-UMIN000000956Institute of Medical Science The University of Tokyo6
已完成
2 期
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000019879Cancer Vaccine Center, Kurume University School of medicine35
招募中
2 期
OCV-C01 as a combination therapy of peptide-based cancer vaccines for patients with advanced biliary tract cancer refractory to priortherapy : Phase II studyJPRN-UMIN000012778Kyushu University Hospital40
已完成
1 期
Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.Completely resected NSCLC, stage IA with vascular invasion and stage IB/II with WT1 antigen positive.JPRN-UMIN000010027Osaka University Graduate School of Medicine, Department of Functional Diagnosis237